Ilodecakin

Drug Profile

Ilodecakin

Alternative Names: Human recombinant interleukin 10; Interleukin-10; Prevascar; rhIL-10; rIL-10; SCH-52000

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Renovo
  • Class Anti-inflammatories; Antineoplastics; Interleukins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Autoimmune disorders; Cancer; Crohn's disease; Graft-versus-host disease; Growth disorders; Hepatic fibrosis; Hepatitis C; Herpes simplex virus infections; HIV infections; Multiple sclerosis; Myocarditis; Pancreatitis; Psoriasis; Reperfusion injury; Rheumatoid arthritis; Scars; Sepsis; Transplant rejection; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 22 Jun 2018 ARMO Biosciences has been acquired by Eli Lilly
  • 06 Jun 2013 ARMO Biosciences completes acquisition of all rights to ilodecakin previously held by Renovo
  • 13 Dec 2012 Targenics agrees to purchase all rights to ilodecakin held by Renovo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top